Advertisement

Clinical Orthopaedics and Related Research®

, Volume 471, Issue 10, pp 3135–3140 | Cite as

What is the Rate of Methicillin-resistant Staphylococcus aureus and Gram-negative Infections in Open Fractures?

  • Antonia F. Chen
  • Verena M. Schreiber
  • Wesley Washington
  • Nalini Rao
  • Andrew R. EvansEmail author
Symposium: 2012 Musculoskeletal Infection Society

Abstract

Background

There have been increasing reports of methicillin-resistant Staphylococcus aureus (MRSA) infections in the community, but it is unclear whether infectious organisms in open fracture infections have changed and if our current regimen of antibiotic prophylaxis is therefore obsolete.

Questions/Purposes

We determined the recent incidence of MRSA and Gram-negative organism infections after open fractures.

Methods

We performed a retrospective cohort study on 189 patients with 202 open fractures treated from 2009 to 2010. During the followup, patients were evaluated for signs of infection using the Centers for Disease Control and Prevention criteria. We determined the organisms using routine microbiology culture. The minimum followup was 3 months (median, 47 months; range, 3–108 months).

Results

Of the 202 open fractures, 20 (10%) developed infections. The most common organism was Staphylococcus, whereas five (25%) of those infected were positive for MRSA, and 11 (55%) of those with infection were cultured for at least one Gram-negative organism. Six (30%) open fractures had infections that grew out multiple organisms. The incidence of MRSA infections in our open fracture population was 2.5%.

Conclusions

There is a high incidence of MRSA and Gram-negative infections after open fractures, which may indicate that current antibiotic regimens need to be changed.

Level of Evidence

Level IV, retrospective case-series. See the Guidelines for Authors for a complete description of levels of evidence.

Keywords

Open Fracture Ceftaroline Type IIIB Ceftaroline Fosamil Type IIIC 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

We thank Dana Farrell for her help with obtaining institutional review board and CARe approval.

References

  1. 1.
    Awad SS, Elhabash SI, Lee L, Farrow B, Berger DH. Increasing incidence of methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: reconsideration of empiric antimicrobial therapy. Am J Surg. 2007;194:606–610.PubMedCrossRefGoogle Scholar
  2. 2.
    Calfee DP. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci, and other Gram-positives in healthcare. Curr Opin Infect Dis. 2012;25:385–394.PubMedCrossRefGoogle Scholar
  3. 3.
    Carsenti-Etesse H, Doyon F, Desplaces N, Gagey O, Tancrede C, Pradier C, Dunais B, Dellamonica P. Epidemiology of bacterial infection during management of open leg fractures. Eur J Clin Microbiol Infect Dis. 1999;18:315–323.PubMedCrossRefGoogle Scholar
  4. 4.
    Dellinger EP, Caplan ES, Weaver LD, Wertz MJ, Droppert BM, Hoyt N, Brumback R, Burgess A, Poka A, Benirschke SK, et al. Duration of preventive antibiotic administration for open extremity fractures. Arch Surg. 1988;123:333–339.PubMedCrossRefGoogle Scholar
  5. 5.
    Dellinger EP, Miller SD, Wertz MJ, Grypma M, Droppert B, Anderson PA. Risk of infection after open fracture of the arm or leg. Arch Surg. 1988;123:1320–1327.PubMedCrossRefGoogle Scholar
  6. 6.
    Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988;16:128–140.PubMedCrossRefGoogle Scholar
  7. 7.
    Glass GE, Barrett SP, Sanderson F, Pearse MF, Nanchahal J. The microbiological basis for a revised antibiotic regimen in high-energy tibial fractures: preventing deep infections by nosocomial organisms. J Plast Reconstr Aesthet Surg. 2011;64:375–380.PubMedCrossRefGoogle Scholar
  8. 8.
    Gustilo R, Merkow R, Templeman D. Current concepts review: the management of open fractures. J Bone Joint Surg Am. 1990;72:299–304.PubMedGoogle Scholar
  9. 9.
    Gustilo RB, Anderson JT. Prevention of infection in the treatment of one thousand and twenty-five open fractures of long bones: retrospective and prospective analyses. J Bone Joint Surg Am. 1976;58:453–458.PubMedGoogle Scholar
  10. 10.
    Gustilo RB, Gruninger RP, Davis T. Classification of type III (severe) open fractures relative to treatment and results. Orthopedics. 1987;10:1781–1788.PubMedGoogle Scholar
  11. 11.
    Gustilo RB, Mendoza RM, Williams DN. Problems in the management of type III (severe) open fractures: a new classification of type III open fractures. J Trauma. 1984;24:742–746.PubMedCrossRefGoogle Scholar
  12. 12.
    Johnson EN, Burns TC, Hayda RA, Hospenthal DR, Murray CK. Infectious complications of open type III tibial fractures among combat casualties. Clin Infect Dis. 2007;45:409–415.PubMedCrossRefGoogle Scholar
  13. 13.
    Johnson KD, Johnston DW. Orthopedic experience with methicillin-resistant Staphylococcus aureus during a hospital epidemic. Clin Orthop Relat Res. 1986;212:281–288.PubMedGoogle Scholar
  14. 14.
    Jorgenson MR, DePestel DD, Carver PL. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Ann Pharmacother. 2011;45:1384–1398.PubMedCrossRefGoogle Scholar
  15. 15.
    Mackenzie EJ, Rivara FP, Jurkovich GJ, Nathens AB, Egleston BL, Salkever DS, Frey KP, Scharfstein DO. The impact of trauma-center care on functional outcomes following major lower-limb trauma. J Bone Joint Surg Am. 2008;90:101–109.PubMedCrossRefGoogle Scholar
  16. 16.
    Ong CT, Choon DS, Cabrera NP, Maffulli N. The treatment of open tibial fractures and of tibial non-union with a novel external fixator. Injury. 2002;33:829–834.PubMedCrossRefGoogle Scholar
  17. 17.
    Patzakis MJ, Harvey JP Jr, Ivler D. The role of antibiotics in the management of open fractures. J Bone Joint Surg Am. 1974;56:532–541.PubMedGoogle Scholar
  18. 18.
    Patzakis MJ, Wilkins J, Moore TM. Considerations in reducing the infection rate in open tibial fractures. Clin Orthop Relat Res. 1983;178:36–41.PubMedGoogle Scholar
  19. 19.
    Poon H, Chang MH, Fung HB. Ceftaroline fosamil: a cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin Ther. 2012;34:743–765.PubMedCrossRefGoogle Scholar
  20. 20.
    Ray GT, Suaya JA, Baxter R. Trends and characteristics of culture-confirmed Staphylococcus aureus infections in a large US integrated health care organization. J Clin Microbiol. 2012;50:1950–1957.PubMedCrossRefGoogle Scholar
  21. 21.
    Rittmann WW, Schibli M, Matter P, Allgower M. Open fractures. Long-term results in 200 consecutive cases. Clin Orthop Relat Res. 1979;138:132–140.PubMedGoogle Scholar
  22. 22.
    Saveli CC, Belknap RW, Morgan SJ, Price CS. The role of prophylactic antibiotics in open fractures in an era of community-acquired methicillin-resistant Staphylococcus aureus. Orthopedics. 2011;34:611–616; quiz 617.Google Scholar
  23. 23.
    Yokoyama K, Itoman M, Shindo M, Kai H. Contributing factors influencing type III open tibial fractures. J Trauma. 1995;38:788–793.PubMedCrossRefGoogle Scholar

Copyright information

© The Association of Bone and Joint Surgeons® 2013

Authors and Affiliations

  • Antonia F. Chen
    • 1
  • Verena M. Schreiber
    • 1
  • Wesley Washington
    • 1
  • Nalini Rao
    • 2
  • Andrew R. Evans
    • 1
    Email author
  1. 1.Department of Orthopaedic SurgeryUniversity of Pittsburgh Medical CenterPittsburghUSA
  2. 2.Department of Medicine, Division of Infectious DiseaseUniversity of Pittsburgh Medical CenterPittsburghUSA

Personalised recommendations